Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 15/20 | 0.62 |
| ▸ | PAK3 | O75914 | 13/20 | 0.62 |
| ▸ | PAK2 | Q13177 | 13/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059652 | 1.00 | PAK1 (0.62) | PAK1PAK3PAK2NTRK1PAK4 | |
| SCHEMBL15091419 | 0.92 | PAK1 (0.64) | PAK1PAK3PAK2NTRK1PAK4 | |
| SCHEMBL15091508 | 0.92 | PAK1 (0.64) | PAK1PAK3PAK2NTRK1PAK4 | |
| SCHEMBL15092005 | 0.90 | PAK1 (0.65) | PAK1PAK3PAK2NTRK1 | |
| SCHEMBL15091765 | 0.90 | PAK1 (0.65) | PAK1PAK3PAK2NTRK1 | |
| SCHEMBL15091519 | 0.90 | PAK1 (0.65) | PAK1PAK3PAK2NTRK1 | |
| SCHEMBL15059009 | 0.87 | PAK1 (0.63) | PAK1PAK3PAK2NTRK1IGF1R | |
| SCHEMBL15091280 | 0.85 | PAK1 (0.64) | PAK1PAK3PAK2NTRK1 | |
| SCHEMBL15208437 | 0.85 | PAK1 (0.58) | PAK1PAK3PAK2NTRK1IGF1R | |
| SCHEMBL15208531 | 0.84 | PAK1 (0.50) | PAK1PAK3PAK2NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | claimed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | PAK1 1/4885PAK3 3/4885PAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.